Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones.
about
Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetesXenobiotic, bile acid, and cholesterol transporters: function and regulation.The challenge of exploiting ABCG2 in the clinic.ABCG2: a perspective.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion.Depression induces poor prognosis associates with the down-regulation brain derived neurotrophic factor of serum in advanced small cell lung cancerInteractions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer.Canalicular ABC transporters and liver disease.Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters.Human ABCG2: structure, function, and its role in multidrug resistance.Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Expression and Activity of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Distal Lung Epithelial Cells In Vitro.Xenobiotic transporters and kidney injury.Renal Drug Transporters and Drug Interactions.The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2).Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.Prediction of Drug Transfer into Milk Considering Breast Cancer Resistance Protein (BCRP)-Mediated Transport.Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.Involvement of breast cancer resistance protein (BCRP/ABCG2) in the secretion of danofloxacin into milk: interaction with ivermectin.Population Pharmacokinetics and Penetration into Prostatic, Seminal, and Vaginal Fluid for Ciprofloxacin, Levofloxacin, and Their CombinationCharacterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters
P2860
Q28482811-708FC22B-5875-48B4-B4E5-DB7EDB6050BCQ33714593-2BB688DE-324E-4557-B5DB-7E59C4284BF9Q34968909-4C89F56E-4AC7-4883-A453-D9DF612F3506Q35016817-F7E9729A-6BA8-4B45-8046-7357DF89C7C6Q35617587-8EA70329-D4FF-4B07-AB8D-24EE6ECCC7A4Q37554392-A330C9D0-EF2C-49CB-BD5F-F98798D6FC37Q37699163-984AB242-E1C9-4A68-8D2F-EB5E70716CA0Q37740126-38B99B22-55DB-4F0A-8EB3-FA1D4FC25554Q37943784-29E2EAE7-BC7C-4C84-9AA4-401038931FBDQ37995676-F67DB1B2-25DC-42ED-B44A-4D748F4171A8Q38003156-3D2005E5-E056-4840-A694-6993BC3EDA2EQ38003174-DE8F487F-D9BA-4141-9FE1-7E69C37C2A43Q38051447-9F2B117E-0ED4-48B5-B1B0-69E9397B6105Q38207943-B54F0E69-5AD2-4C27-9A84-5B782A4E26FDQ38704919-6C7309F2-AF29-4930-93A3-AAF3DE956C79Q39098252-294E6B77-DB05-41D3-9F1F-5B4C56CDAC61Q39140289-A212102A-75DB-4021-B2EE-1C95FC6243ABQ39475570-DE03923D-0E6E-486E-8A06-61D6A4ADAB25Q39883877-347E0331-7E8F-42DD-BF01-FFA36B760A8EQ41413212-E4AFE9ED-D4AB-46FE-9CA6-BC13674EF83FQ47803536-ECC22080-491B-4283-872A-9506DF5DD094Q52710300-ECA1E621-B7A5-4DE6-9958-14EFB728628DQ57240424-8209BBF0-02DE-494E-88B7-87482608F282Q58763717-388B8D5B-F699-4EFA-951A-54DCFA0C71B4
P2860
Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Involvement of breast cancer r ...... mechanism of fluoroquinolones.
@en
type
label
Involvement of breast cancer r ...... mechanism of fluoroquinolones.
@en
prefLabel
Involvement of breast cancer r ...... mechanism of fluoroquinolones.
@en
P2093
P356
P1476
Involvement of breast cancer r ...... mechanism of fluoroquinolones
@en
P2093
Alfred H Schinkel
Hiroyuki Kusuhara
Tomohiro Ando
Yuichi Sugiyama
P304
P356
10.1124/DMD.107.014969
P577
2007-07-16T00:00:00Z